达格列净对伴与不伴2型糖尿病的慢性肾脏病患者肾功能下降速度的影响:DAPA-CKD试验预设分析
DAPA-CKD预设分析纳入4304例伴或不伴2型糖尿病、UACR 200-5000 mg/g且eGFR 25-75 mL/min per 1·73m2的慢性肾脏病患者,随机接受达格列净10 mg每日一次或安慰剂。达格列净较安慰剂使总体队列eGFR下降减缓0·95 mL/min per 1·73 m2每年(95%CI 0·63-1·27),且伴2型糖尿病者慢性eGFR斜率改善幅度大于不伴糖尿病者(交互P=0·0049)。
要点
- 达格列净10 mg每日一次可显著减缓慢性肾脏病患者长期eGFR下降。
- 伴2型糖尿病者eGFR斜率获益大于不伴糖尿病者(交互P=0·0049)。
- 基线HbA1c和UACR越高,eGFR下降越陡,达格列净获益也更明显。
核心结论
- 达格列净较安慰剂显著减缓慢性肾脏病患者的长期eGFR下降。
- 达格列净与安慰剂间eGFR斜率平均差异在伴2型糖尿病、较高HbA1c和较高UACR患者中更大。
研究设计与样本
- DAPA-CKD为随机对照试验,纳入18岁及以上、伴或不伴2型糖尿病、UACR 200-5000 mg/g且eGFR 25-75 mL/min per 1·73m2的参与者。
- 2017年2月2日至2020年4月3日共纳入4304例,2152例(50%)分配至达格列净10 mg每日一次口服,2152例(50%)分配至安慰剂,均加标准治疗。
- 预设分析采用混合效应模型分析基线至第2周、第2周至治疗结束及基线至治疗结束的eGFR斜率。
- 基线平均年龄62岁(SD 12),女性1425例(33·1%),伴2型糖尿病2906例(67·5%);中位在治疗随访2·3年(IQR 1·8-2·6)。
主要发现
- 总体队列中,达格列净较安慰剂使基线至治疗结束eGFR下降减缓0·95 mL/min per 1·73 m2每年(95%CI 0·63-1·27)。
- 基线至第2周,达格列净较安慰剂在伴2型糖尿病者引起急性eGFR下降2·61 mL/min per 1·73 m2(95%CI 2·16-3·06),不伴2型糖尿病者为2·01 mL/min per 1·73 m2(95%CI 1·36-2·66)。
- 第2周至治疗结束,达格列净较安慰剂降低eGFR平均下降速率的幅度在伴2型糖尿病者为2·26 mL/min per 1·73 m2每年(95%CI 1·88-2·64),不伴2型糖尿病者为1·29 mL/min per 1·73 m2每年(95%CI 0·73-1·85;交互P=0·0049)。
- 基线至治疗结束,达格列净较安慰剂对总eGFR斜率下降的影响在伴2型糖尿病者为1·18 mL/min per 1·73 m2每年(95%CI 0·79-1·56),不伴2型糖尿病者为0·46 mL/min per 1·73 m2每年(95%CI -0·10-1·03;交互P=0·040)。
- 基线HbA1c和UACR越高,总eGFR斜率越陡,达格列净对eGFR斜率的影响也更明显。
关键数值与推荐
- 达格列净用法为10 mg每日一次口服,加标准治疗。
- 入组条件:年龄18岁及以上,UACR 200-5000 mg/g,eGFR 25-75 mL/min per 1·73m2。
- 伴2型糖尿病者慢性eGFR斜率平均差异2·26 mL/min per 1·73 m2每年(95%CI 1·88-2·64),不伴者为1·29 mL/min per 1·73 m2每年(95%CI 0·73-1·85;交互P=0·0049)。
临床怎么用
- 对伴或不伴2型糖尿病的慢性肾脏病患者,达格列净可在标准治疗基础上减缓eGFR长期下降。
- 治疗初期可出现急性eGFR下降,第2周后转为慢性斜率获益,解读早期eGFR变化时需考虑此规律。
- 基线HbA1c和UACR较高的患者eGFR下降更陡且达格列净获益更明显,可据此识别获益人群。
局限性
- 本分析为DAPA-CKD试验的预设分析,非独立研究。
- 中位在治疗随访2·3年(IQR 1·8-2·6),长期随访数据有限。
- 研究由AstraZeneca资助。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified analysis, we assessed the effect of dapagliflozin on the rate of change in estimated glomerular filtration rate (eGFR)-ie, the eGFR slope. METHODS: DAPA-CKD was a randomised controlled trial that enrolled participants aged 18 years or older, with or without type 2 diabetes, with a urinary albumin-to-creatinine ratio (UACR) of 200-5000 mg/g, and an eGFR of 25-75 mL/min per 1·73m2. Participants were randomly assigned (1:1) to oral dapagliflozin 10 mg once daily or placebo, added to standard care. In this pre-specified analysis, we analysed eGFR slope using mixed-effect models with different slopes from baseline to week 2 (acute eGFR decline), week 2 to end of treatment (chronic eGFR slope), and baseline to end of treatment (total eGFR slope). DAPA-CKD is registered with ClinicalTrials.gov, NCT03036150, and is now complete. FINDINGS: Between Feb 2, 2017, and April 3, 2020, 4304 participants were recruited, of whom 2152 (50%) were assigned to dapagliflozin and 2152 (50%) were assigned to placebo. At baseline, the mean age was 62 years (SD 12), 1425 (33·1%) participants were women, 2906 (67·5%) participants had type 2 diabetes. The median on-treatment follow-up was 2·3 years (IQR 1·8-2·6). From baseline to the end of treatment, dapagliflozin compared with placebo slowed eGFR decline by 0·95 mL/min per 1·73 m2 per year (95% CI 0·63 to 1·27) in the overall cohort. Between baseline and week 2, dapagliflozin compared with placebo resulted in an acute eGFR decline of 2·61 mL/min per 1·73 m2 (2·16 to 3·06) in patients with type 2 diabetes and 2·01 mL/min per 1·73 m2 (1·36 to 2·66) in those without type 2 diabetes. Between week 2 and end of treatment, dapagliflozin compared with placebo reduced the mean rate of eGFR decline by a greater amount in patients with type 2 diabetes (mean difference in chronic eGFR slope 2·26 mL/min per 1·73 m2 per year [1·88 to 2·64]) than in those without type 2 diabetes (1·29 mL/min per 1·73 m2 per year [0·73 to 1·85]; pinteraction=0·0049). Between baseline and end of treatment, the effect of dapagliflozin compared with placebo on the decline of total eGFR slope in patients with type 2 diabetes was 1·18 mL/min per 1·73 m2 per year (0·79 to 1·56) and without type 2 diabetes was 0·46 mL/min per 1·73 m2 per year (-0·10 to 1·03; pinteraction=0·040). The total eGFR slope was steeper in patients with higher baseline HbA1c and UACR; the effect of dapagliflozin on eGFR slope was also more pronounced in patients with higher baseline HbA1c and UACR. INTERPRETATION: Dapagliflozin significantly slowed long-term eGFR decline in patients with chronic kidney disease compared with placebo. The mean difference in eGFR slope between patients treated with dapagliflozin versus placebo was greater in patients with type 2 diabetes, higher HbA1c, and higher UACR. FUNDING: AstraZeneca.
引用
- Heerspink HJL, Jongs N, Chertow GM, et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021. PMID: 34619108. doi:10.1016/S2213-8587(21)00242-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。